Nemedan (Memantine Hydrochloride)

Memantine hydrochloride, the active ingredient in Nemedan, is a NMDA receptor antagonist presented as an oral tablet for oral use. It treats moderate to severe Alzheimer’s disease in adults.

GNH USA supplies Nemedan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine is used in the management of Alzheimer’s disease, acting on the glutamatergic pathway to provide symptomatic benefit. - Alzheimer’s disease (moderate to severe): improves cognition and functional abilities - Alzheimer’s disease (any stage): helps maintain daily living activities - Alzheimer’s disease (adjunct to cholinesterase inhibitors): may support memory and behavior

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Fatigue - Insomnia

Serious or Rare Side Effects: - Seizures - Severe allergic reactions (rash, swelling, difficulty breathing) - Hallucinations or psychotic symptoms - Suicidal thoughts or behavior - Cardiac arrhythmias - Liver function abnormalities

Before initiating therapy, consider the following safety measures. - Renal impairment: assess kidney function and adjust dose if needed - History of seizures: monitor closely for seizure activity - Concurrent NMDA antagonists: avoid combined use to prevent additive neurotoxicity - Elderly patients: watch for increased confusion or falls - Pregnancy: safety not established; discuss potential risks with a healthcare professional - Store at room temperature: keep in the original container, protect from moisture and direct sunlight

Memantine may interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity - Ketamine: combined CNS depression and heightened neuropsychiatric effects - Other NMDA antagonists: risk of excessive inhibition of glutamate signaling

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may worsen cognitive impairment - CNS depressants (e.g., benzodiazepines): increased dizziness or sedation - Diuretics: possible alteration of memantine plasma concentrations